The iconic rise of Viagra has consistently remained a benchmark of pharmaceutical success, however its future within the broader sector now presents questions about long-term yields . Copycat versions are undercutting market share, leading to anxieties that supporting companies significantly dependent to Viagra's former position could be a dangerou